back
SEDI Insider filing browser
| Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
|---|---|---|---|---|---|---|
| Filed 2021-05-18 10:52 Tx date 2021-05-13 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Options
90 - Change in the nature of ownership
|
+133,555 vol |
408,555 | |
| Filed 2021-05-18 10:50 Tx date 2021-05-13 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
90 - Change in the nature of ownership
|
-133,555 vol |
1,550,945 | |
| Filed 2021-05-13 18:07 Tx date 2021-05-12 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-219,880.4958
-23,802 vol $9.24 each |
0 | |
| Filed 2021-05-13 18:06 Tx date 2021-05-12 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$9,044
+23,802 vol $0.38 each |
23,802 | |
| Filed 2021-05-13 18:04 Tx date 2021-05-12 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$-9,044.76
-23,802 vol $0.38 each |
1,684,500 | |
| Filed 2021-05-13 18:03 Tx date 2021-05-11 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-176,654.2366
-19,198 vol $9.20 each |
0 | |
| Filed 2021-05-13 18:02 Tx date 2021-05-11 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$7,295
+19,198 vol $0.38 each |
19,198 | |
| Filed 2021-05-13 18:00 Tx date 2021-05-11 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$-7,295.24
-19,198 vol $0.38 each |
1,708,302 | |
| Filed 2021-05-13 17:59 Tx date 2021-05-11 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-805,148.75
-87,500 vol $9.20 each |
0 | |
| Filed 2021-05-13 17:57 Tx date 2021-05-11 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
51 - Exercise of options
|
$47,250
+87,500 vol $0.54 each |
87,500 | |
| Filed 2021-05-13 17:56 Tx date 2019-09-25 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
| Filed 2021-05-13 17:53 Tx date 2021-05-11 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
51 - Exercise of options
|
$-47,250
-87,500 vol $0.54 each |
1,727,500 | |
| Filed 2021-01-15 17:31 Tx date 2021-01-14 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-294,278.9328
-19,581 vol $15.03 each |
0 | |
| Filed 2021-01-15 17:30 Tx date 2021-01-14 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$10,573
+19,581 vol $0.54 each |
19,581 | |
| Filed 2021-01-15 17:29 Tx date 2021-01-14 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Options
51 - Exercise of options
|
$-10,573.74
-19,581 vol $0.54 each |
275,000 | |
| Filed 2021-01-15 17:28 Tx date 2021-01-13 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-81,507.7209
-5,419 vol $15.04 each |
0 | |
| Filed 2021-01-15 17:27 Tx date 2021-01-13 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Common Shares
51 - Exercise of options
|
$2,926
+5,419 vol $0.54 each |
5,419 | |
| Filed 2021-01-15 17:21 Tx date 2021-01-13 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Holder: Merrill Lynch, Pierce, Fenner & Smith Incorporated (Control or Direction)
|
Options
51 - Exercise of options
|
$-2,926.26
-5,419 vol $0.54 each |
294,581 | |
| Filed 2020-12-28 16:32 Tx date 2020-12-23 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+600,000 vol |
1,815,000 | |
| Filed 2020-12-28 16:31 Tx date 2020-12-23 |
$TRIL
Trillium Therapeutics Inc. |
Skvarka, Jan
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+600,000 vol |